{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=57", "query": { "condition": "Advanced Solid Neoplasm", "page": 57 }, "page_size": 10 }, "pagination": { "page": 57, "page_size": 10, "total_count": 3387, "total_pages": 339, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=58&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=56&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T21:16:12.351Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06108479", "title": "Study of DF6215 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Solid Tumor Cancer" ], "interventions": [ { "name": "DF6215", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "KEYTRUDA®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2023-11-28", "completion_date": "2025-12-04", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-11-13T21:16:12.351Z", "location_count": 9, "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06108479" }, { "nct_id": "NCT03522142", "title": "A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "INCB081776", "type": "DRUG" }, { "name": "INCMGA00012", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2018-08-27", "completion_date": "2025-09-10", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-11-13T21:16:12.351Z", "location_count": 9, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Hackensack, New Jersey + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03522142" }, { "nct_id": "NCT00003073", "title": "Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Leukemia", "Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "liposomal cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pacira Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 15, "start_date": "1997-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-03-23", "last_synced_at": "2026-11-13T21:16:12.351Z", "location_count": 5, "location_summary": "Los Angeles, California • Stanford, California • Dallas, Texas + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003073" }, { "nct_id": "NCT06120283", "title": "BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Advanced Breast Cancer", "Metastatic Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Hormone Receptor Positive Malignant Neoplasm of Breast", "HER2-negative Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer" ], "interventions": [ { "name": "BGB-43395", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Elacestrant", "type": "DRUG" }, { "name": "Anti-Diarrheal Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 433, "start_date": "2023-12-01", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-13T21:16:12.351Z", "location_count": 9, "location_summary": "Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120283" }, { "nct_id": "NCT07190469", "title": "PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer (TNBC)", "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "PQ203", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ProteinQure Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-09-16", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-11-13T21:16:12.351Z", "location_count": 3, "location_summary": "Houston, Texas • San Antonio, Texas • West Valley City, Utah", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07190469" }, { "nct_id": "NCT05221320", "title": "Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumor, Solid", "Gastrointestinal Cancer" ], "interventions": [ { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioMed Valley Discoveries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2022-05-26", "completion_date": "2024-07-14", "has_results": true, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-11-13T21:16:12.351Z", "location_count": 9, "location_summary": "Tucson, Arizona • San Francisco, California • Fairway, Kansas + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05221320" }, { "nct_id": "NCT05580770", "title": "Mirdametinib + BGB-3245 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Mirdametinib 2mg", "type": "DRUG" }, { "name": "BGB-3245 5mg", "type": "DRUG" }, { "name": "Mirdametinib 3mg", "type": "DRUG" }, { "name": "Mirdametinib 4mg", "type": "DRUG" }, { "name": "BGB-3245 10mg", "type": "DRUG" }, { "name": "BGB-3245 20mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2023-02-03", "completion_date": "2025-01-15", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-13T21:16:12.351Z", "location_count": 6, "location_summary": "La Jolla, California • New Haven, Connecticut • Boston, Massachusetts + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05580770" }, { "nct_id": "NCT03220854", "title": "SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Stereotactic radiotherapy", "type": "RADIATION" }, { "name": "Biological: humanized anti-PD-1 monoclonal antibody", "type": "OTHER" }, { "name": "Biological: humanized anti-PD-L1 monoclonal antibody", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "OTHER" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2017-10-10", "completion_date": "2021-09-22", "has_results": true, "last_update_posted_date": "2022-01-10", "last_synced_at": "2026-11-13T21:16:12.351Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03220854" }, { "nct_id": "NCT04682431", "title": "A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Gynecologic Cancer", "Breast Cancer", "Colorectal Cancer", "Gastric Adenocarcinoma", "Lung Adenocarcinoma", "Pancreatic Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "PY159 Single agent dose level 1", "type": "DRUG" }, { "name": "PY159 Single agent dose level 2", "type": "DRUG" }, { "name": "PY159 Single agent dose level 3", "type": "DRUG" }, { "name": "PY159 Single agent dose level 4", "type": "DRUG" }, { "name": "PY159 Single agent dose level 5", "type": "DRUG" }, { "name": "PY159 Single agent dose level 6", "type": "DRUG" }, { "name": "PY159 Single agent dose level 7", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose level 1", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose level 2", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose level 3", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose level 4", "type": "DRUG" }, { "name": "PY159 Single agent dose expansion cohort", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 1", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 2", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 3", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 4", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 5", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ikena Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2020-11-10", "completion_date": "2023-08-31", "has_results": false, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-11-13T21:16:12.351Z", "location_count": 17, "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04682431" }, { "nct_id": "NCT03057145", "title": "Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Prexasertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Geoffrey Shapiro, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2017-03-10", "completion_date": "2021-06-09", "has_results": false, "last_update_posted_date": "2021-09-02", "last_synced_at": "2026-11-13T21:16:12.351Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03057145" } ] }